clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2025-3-4-7-17clinicaloncology-144Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSДаролуамид в сочетании с андроген-депривационной терапией как новый метод лечения метастатического гормоночувствительного рака предстательной железыDaroluamid in combination with androgen-deprivation therapy as a new method of treatment of mHSPCahttps://orcid.org/0000-0002-6276-1716БеркутМ. В.BerkutMaria V.

Беркут Мария Владимировна,

Санкт-Петербург.

St. Petersburg.

berkutv91@gmail.comhttps://orcid.org/0000-0002-5275-482XЗаозерскийО. В.ZaozerskyOleg V.

Заозерский Олег Вячеславович,

Санкт-Петербург.

St. Petersburg.

https://orcid.org/0009-0008-8245-6234ГорлинП. М.GorlinPetr M.

Горлин Петр Михайлович,

Санкт-Петербург.

St. Petersburg.

https://orcid.org/0009-0004-1819-2845КондратьеваА. Г.KondratyevaAnastasia G.

Кондратьева Анастасия Геннадьевна,

Санкт-Петербург.

St. Petersburg.

https://orcid.org/0000-0003-3850-7109НосовА. К.NosovAlexander K.

Носов Александр Константинович,

Санкт-Петербург.

St. Petersburg.

Национальный медицинский исследовательский центр онкологии им. Н. Н. ПетроваРоссияNational Medical Research Center of Oncology named after N. N. PetrovRussian Federation20250608202634717Copyright © Беркут М.В., Заозерский О.В., Горлин П.М., Кондратьева А.Г., Носов А.К., 20262026Беркут М.В., Заозерский О.В., Горлин П.М., Кондратьева А.Г., Носов А.К.Berkut M.V., Zaozersky O.V., Gorlin P.M., Kondratyeva A.G., Nosov A.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/144

Представлен клинический случай ведения пациента с метастатическим гормоночувствительным раком предстательной железы и высокой метастатической нагрузкой, получавшего терапию даролутамидом в сочетании с андрогенной депривационной терапией. Выбор схемы был обусловлен выраженной сопутствующей патологией и высоким риском межлекарственных взаимодействий, вследствие чего врачебная комиссия определила целесообразность применения препарата с благоприятным профилем безопасности. На фоне лечения отмечается существенный клинический эффект, включая достижение неопределяемого уровня простатспецифического антигена и частичный регресс метастатических очагов. Особое внимание уделено обсуждению значимости проблемы риска развития межлекарственных взаимодействий и роли даролутамида в терапии пациентов старшей возрастной группы с полипрагмазией.

This clinical case report presents the management of a patient with high-volume hormone-sensitive metastatic prostate cancer treated with a combination of darolutamide and androgen deprivation therapy. The treatment choice was driven by significant comorbidities and a high risk of drug–drug interactions, supporting the rationale for selecting a therapy with a favorable safety and interaction profile. The patient achieved a marked clinical benefit, including an undetectable PSA level and partial regression of metastatic lesions. Special attention is given to the clinical relevance of drug–drug interactions and the role of darolutamide in managing elderly patients with polypharmacy.

метастатический гормоночувствительный рак предстательной железыARANOTEдаролутамиддоцетакселандрогендепривационная терапияmetastatic hormone-sensitive prostate cancerARANOTEdarolutamidedocetaxelandrogen-deprivation therapyReferencesКаприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2024 году / под ред. А.Д.Каприна. М.: МНИОИ им. П.А.Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025. 275 с. ISBN 978-5-85502-309-1; URL: https://glavonco.ru/upload/onco2024.pdf (дата обращения 17.12.2025).Kaprin A.D., Starinsky V.V., Shakhzadova A.O. The state of oncological care for the population of Russia in 2024. Ed. by A.D.Kaprin. Moscow: P.A.Herzen Moscow Oncology Research Institute branch of the Federal State Budgetary Institution «NMITs Radiology» of the Ministry of Health of the Russian Federation, 2025. 275 p. ISBN: 9785-85502-309-1; URL: https://glavonco.ru/upload/onco2024.pdf (date of access 17.12.2025) (In Russ.).Siegel R.L., Miller K.D., Wagle N.S. et al. Cancer statistics, 2023 // CA: a cancer journal for clinicians. 2023. Vol. 73 (1). P. 17–48. doi: 10.3322/caac.21763.Siegel R.L., Miller K.D., Wagle N.S. et al. Cancer statistics, 2023 // CA: a cancer journal for clinicians. 2023. Vol. 73 (1). P. 17–48. doi: 10.3322/caac.21763.Harris W.P., Mostaghel E.A., Nelson P.S. et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature clinical practice // Urology . 2009. Vol. 6 (2). P. 76–85. doi: 10.1038/ncpuro1296.Harris W.P., Mostaghel E.A., Nelson P.S. et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature clinical practice // Urology . 2009. Vol. 6 (2). P. 76–85. doi: 10.1038/ncpuro1296.Leith A., Ribbands A., Kim J. et al. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan // BMC urology. 2022. Vol. 22 (1). P. e33. doi: 10.1186/s12894-022-00979-9.Leith A., Ribbands A., Kim J. et al. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan // BMC urology. 2022. Vol. 22 (1). P. e33. doi: 10.1186/s12894-022-00979-9.Aly M., Leval A., Schain F. et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden // Scandinavian journal of urology. 2020. Vol. 54 (2). P. 115–121. doi: 10.1080/21681805.2020.1739139.Aly M., Leval A., Schain F. et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden // Scandinavian journal of urology. 2020. Vol. 54 (2). P. 115–121. doi: 10.1080/21681805.2020.1739139.Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial // Journal of clinical oncology. 2018. Vol. 36 (11). P. 1080–1087. doi: 10.1200/JCO.2017.75.3657.Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial // Journal of clinical oncology. 2018. Vol. 36 (11). P. 1080–1087. doi: 10.1200/JCO.2017.75.3657.Huggins С. Studies on prostatic cancer: The effects of castration on advanced carcinoma of the prostate gland // Archives of Surgery. 1941. Vol. 43 (2). P. 209–223. doi: 10.1001/archsurg.1941.01210140043004.Huggins С. Studies on prostatic cancer: The effects of castration on advanced carcinoma of the prostate gland // Archives of Surgery. 1941. Vol. 43 (2). P. 209–223. doi: 10.1001/archsurg.1941.01210140043004.Clarke N.W., Ali A., Ingleby F.C. et al. Addition of docetaxel to hormonal therapy in lowand high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial // Annals of oncology . 2019. Vol. 30 (12). P. 1992–2003. doi: 10.1093/annonc/mdz396.Clarke N.W., Ali A., Ingleby F.C. et al. Addition of docetaxel to hormonal therapy in lowand high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial // Annals of oncology . 2019. Vol. 30 (12). P. 1992–2003. doi: 10.1093/annonc/mdz396.Fizazi K., Tran N., Fein L. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer // The New England journal of medicine. 2017. Vol. 377 (4). P. 352–360. doi: 10.1056/NEJMoa1704174.Fizazi K., Tran N., Fein L. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer // The New England journal of medicine. 2017. Vol. 377 (4). P. 352–360. doi: 10.1056/NEJMoa1704174.Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer // The New England journal of medicine . 2019. Vol. 381 (2). P. 121–131. doi: 10.1056/NEJMoa1903835.Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer // The New England journal of medicine . 2019. Vol. 381 (2). P. 121–131. doi: 10.1056/NEJMoa1903835.Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer // The New England journal of medicine. 2019. Vol. 381 (1). P. 13–24. doi: 10.1056/NEJMoa1903307.Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer // The New England journal of medicine. 2019. Vol. 381 (1). P. 13–24. doi: 10.1056/NEJMoa1903307.Saad F., Vjaters E., Shore N. et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial // Journal of clinical oncology. 2024. Vol. 42 (36). P. 4271–4281. doi: 10.1200/JCO-24-01798.Saad F., Vjaters E., Shore N. et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial // Journal of clinical oncology. 2024. Vol. 42 (36). P. 4271–4281. doi: 10.1200/JCO-24-01798.Smith M.R., Hussain M., Saad F. et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer // The New England journal of medicine. 2022. Vol. 386 (12). P. 1132–1142. doi: 10.1056/NEJMoa2119115.Smith M.R., Hussain M., Saad F. et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer // The New England journal of medicine. 2022. Vol. 386 (12). P. 1132–1142. doi: 10.1056/NEJMoa2119115.Fizazi K., Foulon S., Carles J. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design // Lancet. 2022. Vol. 399 (10336). P. 1695–1707. doi: 10.1016/S01406736(22)00367-1.Fizazi K., Foulon S., Carles J. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design // Lancet. 2022. Vol. 399 (10336). P. 1695–1707. doi: 10.1016/S01406736(22)00367-1.ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT. URL: https://www.bayer.com/en/us/news-stories/nubeqa-androgen-receptor-inhibitor (date of access 10.12.2025). Text : electronic.ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT. URL: https://www.bayer.com/en/us/news-stories/nubeqa-androgen-receptor-inhibitor (date of access 10.12.2025). Text : electronic.Benzo R., Moreno P.I., Fox R.S. et al. Comorbidity burden and health-related quality of life in men with advanced prostate cancer // Research square. 2023. Vol. 3. P. e2572781 (electronic). doi: 10.21203/rs.3.rs-2572781/v1.Benzo R., Moreno P.I., Fox R.S. et al. Comorbidity burden and health-related quality of life in men with advanced prostate cancer // Research square. 2023. Vol. 3. P. e2572781 (electronic). doi: 10.21203/rs.3.rs-2572781/v1.Ibáñez C., Tourís-Lores M., Montesa M. et al. Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage // Expert opinion on drug metabolism & toxicology. 2025. Vol. 21 (6). P. 625–636. doi: 10.1080/17425255.2025.2478167.Ibáñez C., Tourís-Lores M., Montesa M. et al. Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage // Expert opinion on drug metabolism & toxicology. 2025. Vol. 21 (6). P. 625–636. doi: 10.1080/17425255.2025.2478167.Ruplin A., Segal E., McFarlane T. Review of drug-drug interactions in patients with prostate cancer // Journal of oncology pharmacy practice. 2024. Vol. 30 (6). P. 1057–1072. doi: 10.1177/10781552241238198.Ruplin A., Segal E., McFarlane T. Review of drug-drug interactions in patients with prostate cancer // Journal of oncology pharmacy practice. 2024. Vol. 30 (6). P. 1057–1072. doi: 10.1177/10781552241238198.Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial // The Lancet. Oncology. 2013. Vol. 14 (2). P. 149–158. doi: 10.1016/S1470-2045(12)70560-0.Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial // The Lancet. Oncology. 2013. Vol. 14 (2). P. 149–158. doi: 10.1016/S1470-2045(12)70560-0.

The authors declare that there are no conflicts of interest present.